Evidence map›Paper›PMID 29138877›Full record

ArticlePsychopharmacology2018

Δ

Michael B Gatch, Michael J Forster

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. ΔDrug and alcohol dependence · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michael B GatchDepartment of Pharmacology & Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107-2699, USA. michael.gatch@unthsc.edu.
Michael J ForsterDepartment of Pharmacology & Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107-2699, USA.
University of North Texas · US

Funding

NIDA NIH HHS HHSN271201300001CNIDA NIH HHS N01DA-13-8908
6 · The paper itself

Abstract

RATIONALE AND

objectivesNovel synthetic cannabinoid compounds continue to appear in the market advertised as legal alternatives to marijuana and the older synthetic cannabinoid compounds which are now controlled substances. Most of these newer compounds have been found to act at CB1 receptors, so the purpose of this study was to study the abuse liability of these compounds.

methodsFive of these compounds (BB-22, FUB-PB-22, 5F-AMB, NM2201, and MAB-CHMINACA) were tested for their ability to produce discriminative stimulus effects similar to Δ

resultsAll five of the test compounds fully substituted for the discriminative stimulus effects of Δ

conclusionsThese findings suggest that all five of the test compounds produced Δ

Indexed as

AnimalsCannabinoid Receptor AntagonistsCannabinoidsDiscrimination LearningDose-Response Relationship, DrugDronabinolHallucinogensMaleMotor ActivityRatsRats, Sprague-DawleyReceptor, Cannabinoid, CB1RimonabantCannabinoid Receptor AntagonistsCannabinoidsDronabinolHallucinogensmethyl (1-(5-fluoropentyl)-1H-indazole-3-carbonyl)valinateReceptor, Cannabinoid, CB1RimonabantAbuse liabilityCannabinoidsDrug discriminationLocomotor activityMouseRat

Identifiers

PMID29138877
PMCPMC5823726
OpenAlexW2768174305

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.